Antibodies targeting immune checkpoints such as the programmed death-1 (PD-1) receptor, its ligand PD-L1, or cytotoxic T lymphocyte-associated-4 (CTLA-4) have transformed the treatment of many tumor types. Here, CTLA4 is linked to neoplasm.